Overview

PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy

Status:
Completed
Trial end date:
2013-03-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the treatment effect of panitumumab in combination with FOLFOX compared to FOLFOX alone as first line therapy for metastatic colorectal cancer
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Fluorouracil
Oxaliplatin
Panitumumab